ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Bimetallic Nanozyme Amplifier for Synergistic Ferroptosis-Cuproptosis and Metabolic Reprogramming to Reshape Immunosuppressive Tumor Microenvironment.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Emerging copper-based hollow nanoplatforms for cancer treatment.International journal of pharmaceutics: X · 2026Review
- Cuproptosis and ferroptosis: signal pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Real-time NIR-II fluorescence imaging-guided precision thrombolysis with a molecularly planarized phototheranostic agent.Chemical science · 2026Article
- Article
- Integrated transcriptomic analysis and machine learning identify immunogenic cell death genes as prognostic markers and therapeutic targets in non-small cell lung cancer.Translational cancer research · 2026Article
- Nanozyme for precision treatment of hepatocellular carcinoma.Materials today. Bio · 2026Review
- Advances in artificial metabzymes for macrophage polarization in tumor metabolic immunotherapy.Materials today. Bio · 2026Article
- Metabolic reprogramming and immune evasion interaction in the tumor microenvironment promote tumor progression.Frontiers in oncology · 2026Review
- Nanozyme-Driven Ferroptosis-Cuproptosis Interplay in Lung Cancer.International journal of nanomedicine · 2026Review
- Bimetallic Nanozyme Amplifier for Synergistic Ferroptosis-Cuproptosis and Metabolic Reprogramming to Reshape Immunosuppressive Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanozymes in Tumor Microenvironment Modulation for Cancer Therapy.Biomaterials research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Although ferroptosis and cuproptosis have shown potential in tumor therapy, their anti-tumor efficacy remains considerably limited due to aberrant metabolism within tumor cells and the immunosuppressive tumor microenvironment (TME). Herein, metal-organic framework nanoparticles (PEG@AuCZ@CC) are engineered by incorporating Au nanoparticles and α-Cyano-4-hydroxycinnamic acid (CHCA), to maximize hydrogen peroxide production and induce metabolic shift from aerobic glycolysis to oxidative phosphorylation in tumor cells. Interestingly, metabolic reprogramming of tumor cells not only enhances both ferroptotic and cuproptotic signaling cascades, amplifies immunogenic cell death (ICD) effects, but also reduces intratumoral glucose consumption and extracellular lactate accumulation, thereby creating a glucose-enriched but lactate-depleted TME. Consequently, the platform significantly promotes dendritic cells maturation, enables epigenetic reprogramming of tumor-associated macrophages (TAMs), and restores CD4⁺/CD8⁺ T-cells functionality. This multimodal strategy reshapes the tumor microenvironment (TME) by integrating cell death modulation and cell metabolism regulation, effectively overcoming immune tolerance, presenting a promising paradigm for hepatocellular carcinoma (HCC) therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.